Dear editor
We appreciate very much the supportive and appreciative comments of Drs Kaya and Aksoy regarding the benefits of dietary supplementation with polyunsaturated fatty acids (PUFAs) for improving dry eye symptoms, in this particular case, in patients with glaucoma using topical antihypertensive drugs. Based on a number of clinical studies on the same topic previously published in the literature, there is sufficient evidence for insistently recommending supplementation with omega-3 PUFA in patients with chronic dry eye symptoms, mainly in those not fully satisfied with the use of artificial tears free of conservatives. In intervention trials, both open-label studies with a large population of patients with dry eye symptoms,1 and in controlled trials with smaller samples of patients presenting with dry eye syndrome either due to refractive surgery2 or other causes,3,4 as well as in patients with primary open-angle glaucoma5 suffering from dry eye symptoms related to the chronic use of topical antiglaucoma medications, statistically significant improvements of dry eye signs and symptoms were consistently found in the supplemented group as compared to nonsupplemented patients or healthy controls. Moreover, the expression of cytokine markers in reflex tear samples was also significantly reduced in the supplementation group. These results have also been replicated in a double blind placebo-controlled trial in patients with dry eye symptoms due to meibomian gland dysfunction.6 A statistically significant improvement in health-related quality of life7 among patients in the supplemented group versus controls was another remarkable finding of the trial. These observations are clinically relevant and have direct practical implications, since oral supplementation with omega-3 fatty acids has been demonstrated to be an effective and advantageous option for the relief of persistent and annoying symptoms of dry eye in a variety of ophthalmological settings.
References
-
1.Oleñik A. Effectiveness and tolerability of dietary supplementation with a combination of omega-3 polyunsaturated fatty acids and antioxidants in the treatment of dry eye symptoms: results of a prospective study. Clin Ophthalmol. 2014;8:169–176. doi: 10.2147/OPTH.S54658. [DOI] [PMC free article] [PubMed] [Google Scholar]
-
2.Ong NH, Purcell TL, Roch-Levecq AC, et al. Epithelial healing and visual outcomes of patients using Omega-3 oral nutritional supplements before and after photorefractive keratectomy: a pilot study. Cornea. 2013;32(6):761–765. doi: 10.1097/ICO.0b013e31826905b3. [DOI] [PubMed] [Google Scholar]
-
3.Kangari H, Eftekhari MH, Sardari S, et al. Short-term consumption of oral omega-3 and dry eye syndrome. Ophthalmology. 2013;120(11):2191–2196. doi: 10.1016/j.ophtha.2013.04.006. [DOI] [PubMed] [Google Scholar]
-
4.Pinazo-Duran MD, Galbis-Estrada C, Pons-Vazquez S, et al. Effects of a Nutraceutical formulation based on the combination of antioxidants and ω-3 essential fatty acids in the expression of inflammation and immune response mediators in tears from patients with dry eye disorders. Clin Interv Aging. 2013;8:139–148. doi: 10.2147/CIA.S40640. [DOI] [PMC free article] [PubMed] [Google Scholar]
-
5.Galbis-Estrada C, Pinazo-Duran MD, Cantu-Dibildox J, et al. Patients undergoing long-term treatment with antihypertensive eye drops responded positively with respect to their ocular surface disorder to oral supplementation with antioxidants and essential fatty acids. Clin Interv Aging. 2013;8:711–719. doi: 10.2147/CIA.S43191. [DOI] [PMC free article] [PubMed] [Google Scholar]
-
6.Oleñik A, Jiménez-Alfaro I, Alejandre-Alba N, Mahillo-Fernández I. A randomized, double-masked study to evaluate the effect of omega-3 fatty acids supplementation in meibomian gland dysfunction. Clin Interv Aging. 2013;8:1133–1138. doi: 10.2147/CIA.S48955. [DOI] [PMC free article] [PubMed] [Google Scholar]
-
7.Oleñik A, Jiménez-Alfaro I, Alejandre-Alba N, et al. Benefits of omega-3 fatty acid dietary supplementation on health-related quality of life in patients with meibomian gland dysfunction. Clin Ophthalmol. 2014;8:831–836. doi: 10.2147/OPTH.S62470. [DOI] [PMC free article] [PubMed] [Google Scholar]